COMMIT: A Randomized Study of mFOLFOX6/Bevacizumab/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal Cancer

By afschroeder • July 30, 2026

Rocha Lima CMSP, Yothers G, George TJ, Hochster HS, Sanoff HK, Cohen DJ, Guthrie KA, Jacobs SA, Saeed A, Kopetz S, Colangelo LH, Freeman TJ, Cole SW, Khalil M, Devanna S, Zuckerman DS, Hong TS, Henry NL, Ganz PA, Blanke CD, Wolmark N, Overman MJ. COMMIT: A Randomized Study of mFOLFOX6/Bevacizumab/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal Cancer. J Clin Oncol. 2026 Jul 29:JCO2503052. doi: 10.1200/JCO-25-03052. Epub ahead of print. PMID: 42525921.

Tags: Hematology/Oncology, Publications

Risk factors of immune-related adverse events in patients with early-stage breast cancer: Findings from a multi-institutional retrospective study

LeVee A, Jacob S, Fisch S, Face C, Chengappa M, Chaudhry S, Baclig N, Soliman A, Ruel N, Wong M, Tsai K, Kang I, Kordic[...]

Recurrent prostate adenocarcinoma after radical prostatectomy: Principles of multidisciplinary management across a spectrum of disease

Kishan AU, Zekster Y, Singer AE, Taparra K, Valle LF, Steinberg ML, Nickols NG, Reiter RE, Czernin J, Calais J, Lee JK, Hardesty LR, Rettig[...]

Divergent evolution in bilateral prostate cancer: a case study

Haas R, Huang RR, Weiner AB, Patel Y, Liu LY, Yamaguchi TN, Agrawal R, Boutros PC, Reiter RE. Divergent evolution in bilateral prostate cancer: a[...]